Drug Profile


Alternative Names: JNJ-375; JNJ-64179375

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge University Hospitals; University of Cambridge
  • Developer Janssen Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 18 Aug 2017 Janssen plans a phase II trial for Thrombosis (In patients undergoing total knee replacement surgery) in USA, Argentina, Belgium, Brazil, Bulgaria, Canada, Hungary, Japan, Malaysia, Romania, Russia, Spain, Sweden, Turkey and Ukraine (NCT03251482)
  • 27 Jun 2017 Janssen Research & Development initiates enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT03080987)
  • 17 Mar 2017 Janssen plans a phase I trial for in Healthy volunteers in United Kingdom (NCT03080987)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top